key: cord-0066872-4282o950
authors: Godoy, D.A.; Graneros, N.; Oyarzabal, L.; Murillo-Cabezas, F.
title: High-flow oxygen therapy in acute hypoxemic respiratory failure secondary to COVID-19 pneumonia()
date: 2021-08-21
journal: Med Intensiva (Engl Ed)
DOI: 10.1016/j.medine.2021.08.009
sha: 06a47e7e87e89f6fc884aba03d353f8fbae3a255
doc_id: 66872
cord_uid: 4282o950

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 

We have been reading with great interest the scientific letter written by González-Castro et al. concluding that high-flow oxygen therapy (HFOT) is not an effective therapy, in clinical or economic terms, to treat acute hypoxemic respiratory failure due to SARS-CoV-2-induced pneumonia. 1 As far as we know, statements like this should be taken with caution due to the limitations of the analysis.

Oxygen therapy is one of the main pillars for the management of this particular entity. To this date, multiple techniques have become available including the use of high-flow nasal cannulae (HFNC) that also optimize the conditions of the gas administered (temperature, humidity) with a more reliable FiO2. 2 Physiologically speaking, it offers some attractive advantages and is very well-tolerated. 2 Additionally, HFOT is versatile and can be used in the emergency room or in general rooms. This is an important advantage especially when the resources or beds available at the intensive care unit setting are scarce. Different consensus documents and clinical practice guidelines from various scientific societies advocate for the use of HFOT. 3, 4 Some controversial issues here are the risk of aerosolization and its impact on the rates of intubation and mortality. 2 A meta-analysis conducted before the pandemic confirmed that HFOT reduces the need for increasing ventilatory support including invasive mechanical ventilation. 5 However, uncertainty surrounds COVID-19-induced pneumonia due to the heterogeneity of the studies conducted on several aspects reported. Therefore, no valid conclusions can be drawn to this date on this regard (table 1) . Therefore, the retrospective nature of the study and its small sample do not let us draw any conclusive statements yet. However, we should reflect on the data provided from a different angle. Only 20 patients (30% of the population) received HFOT. A total of 12 of these patients (60%) did not need to be escalated to ventilatory support and had shorter ICU and hospital stays. Also, no deaths were reported. No information on costeffectiveness in this population has been disclosed. In our opinion, this situation cannot be considered a failure whatsoever.

On the other hand, when patients who remained «unresponsive and required invasive ventilation» were studied, the HFOT was implemented with further delay, they were older patients with more comorbidities, and worse oxygenation indices prior to the indication for HFOT, which makes us wonder:

1. Would an earlier implementation of HFOT increase its effectiveness? 2. Does HFOT affect all patients the same way or is it more beneficial for certain subgroups of patients? 3. Does awake prone positioning plus HFOT increase the effectiveness of this oxygenation technique?

On the other hand, the protocols of initiation and withdrawal of HFOT are heterogeneous across the world, but they have not been universally validated yet. Our preliminary experience (data still unpublished) in 2 regions and in different countries is encouraging, especially regarding the association between HFOT and the awake prone positioning through the implementation of clinical guidelines or protocols since hospital admission. For all these reasons, we believe it is important to conduct well-designed studies to shed light on all these issues.

J o u r n a l P r e -p r o o f COT, conventional oxygen therapy; CPAP, continuous positive airway pressure; FiO2, fraction of inspired oxygen; HFOT, high-flow oxygen therapy; lpm, liters per minute; N/A, non-applicable; SpO2, oxygen saturation; T, temperature.

Oxigenoterapia de alto flujo en el tratamiento de la neumonía por SARS-CoV-2

High-Flow, Noninvasive Ventilation and Awake (Nonintubation) Proning in Patients With Coronavirus Disease 2019 With Respiratory Failure

Clinical consensus recommendations regardingnon-invasive respiratory support in the adult patient with acute respiratory failure secondary to SARS-CoV-2 infection

The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline

Highflow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission